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Abstract
As the third most common cancer of the gastrointestinal tract, esophageal cancer has a 
rather worse prognosis treated with current therapy strategies, and a poor 5-year survival 
rate lower than 15%. Recent years, emerging immunotherapy has showed a gratifying 
effect in treating other solid tumors which illuminates its usage for esophageal cancers. 
Immunotherapy for esophageal cancer basically includes adoptive-cell-therapy-based, 
antibody-based and vaccine-based therapies, and all of which have shown preliminary 
favorable results in treating esophageal cancer. However, due to the rather lower muta-
tion rate and a tough microenvironment inside the cancer, promising immunotherapies 
like immune checkpoint blockade drugs, gene-modified-T cell therapies are hindered by 
the immunosuppressive factors from microenvironment. Future endeavors will be focus-
ing on targeting immunosuppressive factors, combining immunotherapies with classical 
treatments to create a satisfying effect.
Keywords: esophageal cancer, tumor microenvironment, immunotherapy, immune 
checkpoint blockade drugs, CAR-T cell therapy
1. Introduction
Esophageal cancer is one of the leading culprits of mortality worldwide and is responsible for 
a total number of 746,000 [1] new cases and 439,000 [2] deaths every year. A large number of 
these cancers are diagnosed at an advanced stage and the metastasis causes bad outcomes. 
Endoscopic surgery, cytotoxic chemotherapy and radiotherapy remain to be the active and 
essential clinical treatment but only provide modest benefits, with median overall survival 
(OS) only in the range of 8–10 months [3]. After nearly 20 years of fast development, immu-
notherapy turned to be a promising method for treating esophageal cancer. Recent advances 
have brought some therapeutic regimens to be approved by Food and Drug Administration 
(FDA) then coming to clinical practice in first- and second-line settings (Table 1). The future 
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Treatment Cancer type Treating method Phase Study number
ACT





EC NY-ESO-1-TCR T cells II NCT01795976
Tumor vaccine
Cell vaccine Multiple cancer 
types (including 
EC)








Allogeneic tumor vaccine I NCT01143545
Peptide vaccine EC IMF-001 I NCT01003808
EC LY6K, VEGFR1, VEGFR2 I NCT00561275
EC URLC10, TTK, KOC1, VEGFR1, 
VEGFR2, cisplatin, fluorouracil
I NCT00632333
EC URLC10 I NCT00753844




EC + GEJC + GC Nivolumab/placebo III NCT02743494
EC + GEJC 
Siewert I
Pembrolizumab vs. investigator’s choice III NCT02564263
EC Pembrolizumab + brachytherapy I NCT02642809
EC Nivolumab vs. paclitaxel/docetaxel III NCT02569242
EC + GEJC 
Siewert I
Pembrolizumab II NCT02971956











Nivolumab + ipilimumab I NCT02834013
ACT: adoptive cell therapy; CIK: cytokine-induced killer cells; CTL: cytotoxic T-cells; VEGFR: vascular endothelial 
growth factor receptors; PD: programmed cell death receptor; EC: esophageal cancer; ESCC: esophageal squamous cell 
carcinoma; GEJC: gastroesophageal junction carcinoma.
Table 1. Recent or completed clinical trials of potential therapeutic approaches for immunotherapy of esophageal cancer.
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of immunotherapy is promising in treating solid tumors, yet still there is a desperate need for 
more effective and less toxic treatment options for patients with advanced esophageal cancer.
In recent years, emergence of immunotherapy towards cancer has improved the manage-
ment of several malignancies dramatically, especially melanoma, renal cell carcinoma, non-
small cell lung cancer and so on, shedding light on its usage on esophageal cancer as well. 
Identification of more suppressive factors in tumor microenvironment and insights into the 
biology of T cell functioning yielded a large number of diverse and novel anti-tumor regi-
mens. Global efforts continue to explore how and when to integrate these agents in treatment 
of esophageal cancer. Immune checkpoint inhibition through antibodies that block cytotoxic 
T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has led to 
meaningful improvements in survival [4]. Vaccine adjuvant administration has also reduced 
tumor recurrence to some degree. CAR-T (chimeric antigen receptor T-cell) immunotherapy 
is a typical example of recent advances in synthetic biology, genome engineering, and cell 
manufacturing that has made it possible to develop highly specific and potent tumor-reactive 
T cells and offer many opportunities for experimentation and broader clinical translation. 
Combined regimens of immunotherapy with other classical esophageal treating procedures 
will illuminate the future of clinical oncotherapy. Recent achievements, which are illustrated 
below, including finished or ongoing clinical trials and laboratory findings of immunotherapy 
for esophageal cancer, bringing optimism for meaningful changes in treatment algorithms 
and for better outcomes in this fatal disease.
2. Immunotherapy regimens for esophageal cancer
2.1. History of immunotherapy
A few decades ago, several rare clinical regression of advanced cancer in response to immune 
stimulation aroused interests in the area of cancer treatment. A passionate handful of immu-
nologists, oncologists and surgeons carried out forward-looking researches into the relations 
between tumor progress and body immune system. Their respectable efforts turned the seem-
ingly insignificant clinical phenomenon into reproducible concrete success by revealing the 
hidden mechanisms of tumor response.
At the earliest period of cancer immunotherapies, the exact mechanism remained unknown 
and the anti-tumor growth effect was limited yet providing impetus for in-depth study. 
The first effective immunotherapies aiming at directly modulating cell function using well-
characterized recombinant cytokines including interleukin-2 (IL-2) and interferon alpha 
(IFNα), yet the safety was lowered associated with substantial toxicity. Other cytokines, 
including IFNγ, IL-4, IL-7, IL-10, IL-12, IL-15, IL-18, IL-25, etc., failed to provide substantive 
benefit. The following breakthrough was the emerging conception of monoclonal antibod-
ies (mAbs) targeting tumor cell surface receptor proteins (human epidermal growth factor 
receptor 2 (HER2)/Neu, epidermal growth factor receptor (EGFR), etc.) and were integrated 
into cancer care. Vaccination therapies using the modified peptide, whole tumor, recom-
binant proteins, dendritic cells (DCs), and adjuvants were only modestly successful. With 
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researching deeper into the cross-talk happening in the tumor microenvironment between 
tumor cells and immune cells, the modern era of immunotherapy launched with the extraor-
dinary novel efficacy (and toxicities) of mAbs targeting immune checkpoints in patients 
with various cancer types in order to decrease the suppressive potential that would prevent 
immune cells from functioning. Current alternative approach to overcoming the suppressive 
tumor microenvironment was the administration of genetically modified autologous T cells 
targeting specific cancer-related antigens [5]. This could be done in the form of T cells in 
which modified specific T cell receptors (TCR) were inserted for a shared tumor antigen or a 
tumor-specific neoantigen accompanied by co-transduction of stimulatory cytokines such as 
IL-12 or could co-administrate with PD-1 pathway blockers to sustain the capability before 
being expanded in large numbers in vitro following lymphodepleting chemotherapy. These 
approaches have produced dramatic responses in a few patients with a variety of individual 
tumor types, especially hematological malignancies [6]. Further improvement of adoptive cell 
transfer therapy came from the modified T cells expressing chimeric antigen receptors (CAR) 
targeting tumor-specific binding domains. After several generations of amelioration, CAR-T 
therapy showed extraordinary effect in treating hematological malignancies yet treatment of 
patients with solid tumors using CAR-T cells had been less fruitful and had troubled clini-
cians much through the off-tumor/on-target toxicity. Given the virtually limitless possibility 
of ex vivo engineering of T cells, many of these potential hurdles will likely be resolved by the 
additional modification of T cell products prior to treatment.
Immunotherapy showed great potential in the treatment of esophageal cancer. Modern 
treatments of patients with esophageal cancer integrated immunotherapy with conventional 
surgical, chemotherapeutic, and radiation oncologic strategies. In spite of the seemingly grati-
fying results, the 5-year survival rate of patients with esophageal cancer in the middle and 
late stages is still lower than 15%, the 5-year survival rate of patients with locally advanced 
surgery alone is only 20–25% [7]. Postoperative chemotherapy or neoadjuvant chemoradia-
tion only turns the 5-year survival rate up to only 30–35% [8]. One of the causes to blame of 
the rather poor prognosis of esophageal cancer is the rapid disease progression. More than 
50% of patients already have visible metastases at the time of diagnosis [7]. Therefore, further 
investigation of esophageal cancer microenvironment and its impact on disease progression 
will lay a solid theoretical foundation for early diagnosis and treatment improvement of 
esophageal cancer.
In this chapter, we tried to converge concepts relevant to the complicated relationship between 
the host and the neoplastic tissue.
2.2. Immune microenvironment and molecular correlations in esophageal cancer
As early as 100 years ago, Paget [9] had put forward the hypothesis of “seeds and soil”, which 
laid the foundation for the concept of tumor microenvironment. Numerous data indicate that 
many immune-related cells, factors and immune-related signaling pathways in the tumor 
microenvironment play an important role in the occurrence, metastasis, recurrence, angio-
genesis, and drug resistance of tumors. The in-depth study of the tumor immune microenvi-
ronment is to search for molecular pathogenesis and new therapeutic models of esophageal 
cancer.
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Tumor microenvironment is constituted by various immune cells, endothelial cells, adipocytes, 
paravascular cells, nerve cells, fibroblasts, and extracellular matrix components around the 
cancer cells [10]. Some stromal cells in the tumor microenvironment have immunosuppressive 
potential to inhibit the function of immune effector cells and promote tumor progression. Thus 
inhibiting cancer cell apoptosis and promoting mechanisms such as proliferation, angiogenesis, 
drug resistance, and immune escape to promote tumorigenesis [11]. Chemokines CCL17 and 
CCL22 secreted by tumor cells or tumor-associated macrophages (TAMs) recruit CCR4+ regula-
tory T cells (Treg), which then inhibit immune effector cells by contacting directly or secretion of 
cytokines (IL-10 and IL-35). Th17 cells can be transformed into Treg cells stimulated by IL-6 and 
transforming growth factor-β (TGF-β). Inflammation and tumor-derived factors stimulate the 
activation of myeloid-derived suppressor cells (MDSCs). Activated MDSCs can directly inhibit 
the expression of CD8 + T cells. Activation and induction of Treg cells and other mechanisms 
contribute to immune escape of cancer cells. TAM cells and CAF cells promote the growth, 
invasion, metastasis, and angiogenesis of tumor cells through the secretion of cytokines, che-
mokines, and various growth factors. In addition, tumor cells and TAM cells can express pro-
grammed cell death ligand (PD)-L1/2 inhibiting T cell activation after binding to PD-1.
MDSCs have been shown to play an important role in promoting tumor immune escape, acti-
vating CAF cells and angiogenesis [12]. The presence of proinflammatory cytokines such as 
IL-1, IL-6 and prostaglandins in esophageal cancer microenvironment can activate MDSC [13]. 
MDSC inhibits activation of T cells by direct inhibition [14], cytotoxicity of natural killer cells 
(NK) [15], depletion of arginine and cysteine, induction of Treg cells, etc. to achieve immune 
escape [16]. Another group of immunosuppressive cells that exert similar functions are Treg 
cells. Under physiological conditions, Treg cells can regulate the activation and proliferation 
of T cells, B cells, and cytotoxicity of NK cells. But in tumor microenvironment, Treg cells 
can promote the occurrence and progression of tumor cells by secreting immunosuppres-
sive related factors, secreting tumor-associated antigens (TAAs), and suppressing the cellular 
adverse reactions of immune effector cells and the release of granzymes [17]. Studies have 
shown that tumor cells and TAMs can recruit CCR4+ Treg cells to tumor sites by secreting 
CCL17 and CCL22 and other chemokines [18]. Treg cells are highly aggregated in tumor cites, 
promoting tumor invasion and metastasis, and are associated with disease severity, survival 
after chemotherapy, and prognosis [17]. Additionally, Th17 cells can secrete IL-17 and IL-22 
and activate STAT3 related signaling pathways to promote angiogenesis and tumor growth 
[23]. However, the role of Th17 cells is still controversial. What factors affect the function of 
Th17 have not yet been well defined [18]. Therefore, we still have to know more about Th17 
cells in esophageal cancer to explore potential therapeutic targets.
The tumorigenic mechanisms of TAMs are varied. Phenotype spectrum of macrophage 
ranges from M1 to M2: M1 macrophages represent the classical activated macrophages, with 
functions of cytokines secretion, antigen presentation, resistance to infection and anti-tumor 
ability, etc., while M2 macrophages secrete type II cytokines and induce activation of COX2/
prostaglandin E and other mechanisms that cause tumorigenesis [19]. The presence of cancer 
associated fibroblasts (CAFs) in patients with esophageal cancer is associated with microves-
sel density, and can also promote tumor progression and metastasis through epithelial mes-
enchymal transition (EMT). CAFs are also associated with 3-year survival rates and disease 
recurrence after radiotherapy and chemotherapy [20].
Immunotherapy for Esophageal Cancer
http://dx.doi.org/10.5772/intechopen.78644
15
PD-1 is a member of the CD28 superfamily and is an important immunosuppressive molecule 
that inhibits the activation of T cells after binding to its ligand PD-L1/PD-L2 [4]. Multiple 
experiments confirmed that PD-L1 and PD-L2 are highly expressed in esophageal cancer [21], 
in which PD-L1 expression is closely related to tumor invasion depth and poor prognosis, 
whereas PD-L2 expression is associated with decreased CD8+ T cell infiltration [21]. The 
increasing PD-L2 expression can promote the secretion of Th2 cytokines such as IL-4/IL-13 
[22]. These pieces of evidence suggest that blockers targeting PD-1 are of great significance in 
the treatment of esophageal cancer [23].
In the early stages of esophageal cancer, TGF-β signaling suppresses tumor growth by down-
regulating the expression of Smad4 and c-Myc genes, while promoting growth and EMT in 
advanced esophageal cancer [24]. This “switching” effect is thought to be caused by the loss of 
adaptor proteins. For instance, an important adaptor protein, β2-spectrin, plays an important 
part in cell–cell interactions and maintenance of epithelial cell polarity. In esophageal adeno-
carcinoma, decreasing β2-spectrin in tumor cells results in increased expression of SOX9 and 
c-Myc, but it also reduces other TGF-β targets such as E-cadherin and cell cycle-regulated 
p21 and p27 genes [25]. In summary, these changes make TGF-β promote the progression 
and metastasis of the tumor by inducing EMT, especially in epithelial tumors like esophageal 
cancer.
In addition to growth factors, chemokines in the tumor microenvironment also play an 
important role in the development of tumors. Mainly, there is stromal cell derived factor-1 
(CXCL12/SDF-1) secreted by fibroblasts [26], binding to its corresponding receptor CXCR4 or 
CXCR7 thus inducing tumor growth, promoting angiogenesis, stimulating tumor movement, 
invasion and metastasis [26]. SDF-1/CXCR4/CXCR7 axis is closely related to tumor invasion, 
metastasis and survival. However, the use of these separate components as indicators of prog-
nostic analysis has yielded inconsistent results [27]. Nonetheless, CXCL12 has been shown to 
regulate the migration of CXCR4-positive tumor cells in esophageal adenocarcinoma in vitro 
and in vivo. Knockout of CXCR4 expression in KYSE-150 and TE-13 esophageal cancer cells 
by small interfering RNA can inhibit the proliferation, invasion and metastasis of tumor cells. 
Local CCL5 and CXCL10 in esophageal squamous cell carcinoma can recruit CD8+ T cells to 
the tumor site [28].
Further researches showed that remodeling body immune state by various means in esopha-
geal cancer patients will be the main research direction of immunotherapy for esophageal 
cancer.
2.3. Checkpoint inhibitor regimens
Immune system has sophisticated regulatory mechanisms. Several checkpoints are involved 
to maintain the balance between effective immune-responses fighting against infection or 
cancer state yet won’t activate excessively to prevent damaging healthy cells. Cytotoxic T lym-
phocyte antigen-4 (CTLA-4) and PD-1 are among the major inhibitory receptors expressed by 
Tregs which downregulate immune responses [29]. Inhibitory antibodies modulating these 
immune checkpoints have been most frequently used in immune-oncology trials in esopha-
geal cancers.
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PD-1/PD-L1 blockers have achieved encouraging clinical results in treating melanoma, lung 
cancer and other cancer types [30, 31]. The potential role of PD-1 blockers in treatment of 
esophageal cancer can be predicted by genomic map of the tumor immune microenviron-
ment. The expression of PD-L1 on MDSCs isolated from esophageal cancer tissue was higher 
obviously, and PD-1 expression was detected in approximately 60% of the tumor infiltrating 
lymphocytes (TILs) from esophageal cancer tissues [32]. Therefore, inhibition of the PD-1/
PD-L1 pathway for esophageal cancer treatment cannot be ignored.
Preliminary results of ongoing studies indicated that PD-1 blocker Pembrolizumab had 
acceptable safety in PD-L1 positive esophageal cancer patients. The objective response rate 
for mid-term analysis was approximately 30% with a sustained response period of up to 
40 weeks [33]. These results laid the foundation for the continued completion of checkpoint 
inhibitor regimens pivotal study in esophageal cancer patients.
CTLA-4, also known as CD152, belongs to the immunoglobulin superfamily and serves as 
an immunological checkpoint. When activated CD4+ helper T cells express CTLA-4, this 
kind of cells sends inhibitory signals to T cells [34]. High CTLA-4 expressing CD4+ Treg cells 
block T cells by reducing IL-2 secretion and downregulating IL-2 receptor expression then 
retard T cells in G1 phase of the cell cycle [35]. Ipilimumab and tremelimumab have two fully 
humanized monoclonal anti-CTLA-4 antibodies that have already received FDA approval 
for the treatment of melanoma and mesothelioma [36, 37]. A survey of tremelimumab has 
been completed in phase II clinical trials for treating advanced gastric and esophageal cancer 
(n = 18). Although only a 5% response rate was observed, four patients were controlled and 
one patient was observed with partial remission (25.4 Mo) after treatment and continued for 
several months [38]. The results of ongoing clinical trials are expected to further highlight the 
clinical value of monoclonal anti-CTLA-4 antibodies in esophageal cancer.
2.4. Vaccine regimens
Tumor vaccine treatment involves the administration of TAAs into patients thus triggering 
specific anti-tumor immune responses. Rosenberg et al. [39, 40] conducted a comprehensive 
review of 1306 cancer vaccine usage studies conducted before 2004 and found that the overall 
target response rate was only 3.3%. The explanation may be that these immune cells have low 
affinity or are inhibited by endogenous factors like the checkpoints mentioned above.
For the treatment of esophageal cancer, some vaccine-based clinical trial reports have been 
published. A Phase I clinical trial of 10 patients with refractory stage III or IV esophageal 
squamous cell carcinoma treated with peptide vaccine found that 9 patients developed 
antigen-specific T cell immune response. One of the patients with liver metastases showed 
complete remission for 7 months, another had partial remission within all metastatic lung 
lesions, and 3 patients had progression-free survival lasting 2.5 months. The peptide vaccine 
used was derived from three HLA-A24-restricted cancer testis antigens (TTK protein kinase, 
lymphocyte antigen 6 complex locus K, and insulin-like growth factor-II mRNA binding 
protein 3) [41]. The multicenter, phase II clinical trial of the vaccine evaluated the OS, PFS, 
and immune response after vaccinations in patients with HLA-A*2402 positive and negative 
esophageal squamous cell carcinoma, and immune response was observed in HLA-A*2402 
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positive patients (n = 35), but there was no statistical difference in OS compared to HLA-
A*2402-negative patients (n = 25) (4.6 mo vs. 2.6 mo, P > 0.05), yet there is a significant dif-
ference in PFS (P = 0.032) [42]. In a tumor vaccine trial hosted by Saito et al. [43] (n = 20), 
4 patients with high levels of MAGE-A4 or MHC class I antigen in autologous tumor cells 
not only showed MAGE-A4 specific immune responses after vaccination, but compared with 
patients without using antibodies, their OS was also significantly prolonged. Wada et al. [44] 
used NY-ESO-1 as a cancer vaccine in 8 patients with esophageal cancer. The results showed 
that 7 patients had an immune response. Of the 6 patients evaluated for efficacy, 1 patient 
experienced partial remission, 2 patients continued to maintain progression-free status, and 2 
patients had mixed clinical responses. Given the preliminary results of these peptide vaccines 
in clinical trials, safety inspections and the related researches combined with radiotherapy 
and chemotherapy are also being carried out gradually in treating multiple cancer types 
including esophageal cancer.
2.5. Adoptive cell therapy regimens
The concept of ACT (adoptive cell therapy) was first proposed by Dietrich et al. [45]. It refers 
to the treatment of utilizing autologous or allogeneic immune cells by infusing them back 
into the patients after being amplified in vitro by certain means. Currently effector cells can be 
divided into two categories: the first type is non-specific immune cells, including autologous 
lymphokine-activated killer cells (LAK), cytokine-induced killer cells (CIK) and NK cells. 
Cells are isolated from peripheral blood cells and are stimulated by lymphokines or cyto-
kines; another type of effector cells is antigen-specific T cells, including TILs, cytotoxic T cells 
(CTL) and genetically engineered T cells including T cell receptor transferred T-cells (TCR-T) 
and CAR-T [46].
The first ACT trial in human improved the survival of patients with metastatic cancer by rein-
troduction of CIK and recombinant IL-2 to their body, which has been successfully applied to 
the treatment of refractory metastatic melanoma, and for other types of cancer such as glioma, 
renal cell carcinoma, non-small cell lung cancer, etc. The objective response rate varies from 20 
to 72% [47], encouraging its further usage in esophageal cancer, too.
So far, ACT treatment of esophageal cancer has been evaluated in several clinical trials. In 
the first published study by Besser et al. [48] and Toh et al. [49], mononuclear cells were iso-
lated from peripheral blood of esophageal squamous cell carcinoma patients and were given 
autologous tumor cell stimulation in vitro. Latter results showed that half of the patients had 
an objective response, and 36% of the subjects achieved complete remission or partial remis-
sion. CTL and TIL cells are now hot spots for carrying out immunotherapy for solid tumors 
as the mechanism of killing tumor is rather clear.
TCR-T cells transduce the α and β chains of the antigen-specific high-affinity TCR into T 
cells and express them on the cell surface, thereby effectively identifying and killing the 
tumor cells expressing the antigen. Currently, the most common TAAs found in esophageal 
cancer are cancer testis MAGE-A3/4 and NY-ESO-1. Several studies [50, 51] showed that 
the expression ratio of MAGE-A3 in esophageal cancer was about 90%, and the expression 
rate of NYESO-1 in esophageal cancer was up to 40–90%. A preliminary phase 1 clinical trial 
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of genetically engineered T cells was carried out by Kageyama et al. [52], TCR-T cells were 
readopted to patients with MAGE-A4-positive recurrent esophageal cancer, and adminis-
tered the MAGE-A4 peptide vaccine subsequently, the level of TCR-T cells in the peripheral 
blood of 10 subjects was monitored for 5 months, and 5 of them were able to detect specific T 
cells continuously. Seven subjects appeared tumor progress after 2 months of treatment, but 
another 3 subjects survived more than 27 months.
CAR-T is another type of genetically engineered T cells. CAR-T was obtained by translocating 
chimeric antigen receptor such as CARs into T cells. Gross et al. [53] successfully constructed 
the structure of CARs into T cells for the first time to exert their specific killing function. Up 
to now, tens of clinical trial data of CAR-T treatment on malignant hematological malignan-
cies have been published. The Novartis’ tisagenlecleucel, a synthetic bioimmune product of 
anti-CD19 CAR-T cells has been approved by FDA on treating relapsed/refractory B-cell acute 
lymphoblastic leukemia (B-ALL) in 2017 [54]. The early generation of CAR-T therapy for solid 
tumors did not appear ideal outcomes during clinical use [55]. The reasonable explanation 
might be lack of unique TAAs in solid tumors, less efficiency and persistency of T cell hom-
ing to tumor sites, and the intratumoral immunosuppressive environment strongly inhibited 
CAR-T cell function. Clinical trials targeting solid tumors using second or third-generation 
CAR techniques had been limited, but some of the more significant clinical trials are carry-
ing out good results. Patients with metastatic or recurrent HER2-positive medulloblastoma 
treated with HER2-CAR-T had came out with stable conditions [56]. Feng et al. [57] showed 
the results of a clinical trial of an EGFR-CAR-T treatment for EGFR-positive relapsed/refrac-
tory NSCLC patients revealed partial remission in 2 of the 11 patients involved in the evalua-
tion and 5 patients had a stable condition ranging from 2 to 8 months. There were no obvious 
adverse reactions in the entire clinical trial. In the treatment of esophageal cancer, no CAR-T 
therapy-related studies have been conducted yet. However, anti-tumor targets are now erupt-
ing in esophageal cancer. Points such as HER2 can also provide references for future steps in 
the development of research.
3. Combined treatment
Currently, comprehensive therapy shed light on tumor treatment to a large degree. Clinical 
practice has proven that it is difficult to achieve the best results with any single treatment 
method. Therefore, the principle of treatment for most tumors depends on comprehensive 
treatment. Recent research results showed that the combined usage of immunotherapy and 
chemotherapy in a variety of cancer treatment achieved better results than a single therapy, 
it can not only reverse the immunosuppression effects caused by the late stage of the tumor, 
increase the cross-presentation of tumor antigens, promote the proliferation of killer T cells 
and make it more easy to kill tumor cells, but can also reduce the incidence of adverse reactions 
from chemotherapy and reduce drug resistance of tumor cells to some extent. Combination 
of chemotherapy and immunotherapy has been a common available method in some cancer 
types. Neoadjuvant chemotherapy regimens together with HER2-targeted therapy achieved 
pathologic complete response in relapse-free survival among patients with breast cancer [58]. 
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New treatment targeting specific mutant genes illustrated clinical success in a phase II study 
of metastatic melanoma combined with interleukin-2 aldesleukin and BRAF inhibitor vemu-
rafenib [59]. The effectiveness of combined therapy can even cover the metastatic areas, in 
melanoma brain metastases, complete intracranial response was observed after using dual 
checkpoint-inhibition of talimogene laherparepvec (T-Vec), pembrolizumab and whole brain 
radiotherapy. Additionally, immunotherapy also showed potential augmented effect plus 
cryotherapy [60], focused ultrasound therapy [61] and photothermal therapy [62], etc. Tumor 
vaccine also took another leap when combined with other immunotherapies, clinical results 
showed that nivolumab in combination with talimogene laherparepvec (T-Vec) in resected 
melanoma carried out better outcomes [63]. The clinical value of immunotherapy and radio-
therapy showed even more outstanding clinical effects, anti-tumor immune response was 
enhanced by anti-PD-1 immunotherapy in recurrent nasopharyngeal carcinoma, showing 
a bright prospect of further combination [64]. In treating esophageal cancer, there are also 
many creative comprehensive treatment methods that are constantly developing. In patients 
with drug-resistant esophageal cancer, a phase Ib/II study of low-dose decitabine-primed 
chemoimmunotherapy showed undeniable safety and efficacy [65]. A combination therapy 
of multi-peptide vaccine with chemoradiation therapy performed satisfying safety thus can 
be an effective treatment for patients with unresectable ESCC [66]. Novel multitarget tyrosine 
kinase inhibitor anlotinib in a third-line treatment of refractory advanced non-small-cell lung 
cancer (RA-NSCLC) provided significant PFS benefits compared with placebo, and accom-
panied with acceptable toxicity [67]. Though has a guaranteed future, there need to be more 
rational and effective trials of combinations to be excavated in the field of treating esophageal 
cancer together with other solid tumors.
4. Conclusions and future directions
The success of immunotherapy in some tumors came from years of research deep into the 
immune system and tumor itself and brought hope of healing cancer. It is worth mentioning 
that several immune checkpoint blockers have been or are being approved by the FDA, and 
it is expected that the next step will be to accelerate the pace of application of single drug 
or other treatment modes in combination within clinical usage. However, opportunities and 
challenges coexist, and there are still some key questions that have not been answered in 
immunotherapy. First of all, many targeted cancer drugs that treat cancer need to be explored 
to determine the biological dose that achieves the greatest clinical benefit with minimal toxic-
ity. Second, given that most of the current immunotherapy is mainly to activate anti-tumor 
effects by activating the immune system, this kind of treatment requires patient to have some 
degree of immunity before receiving the initial immunotherapy. Therefore, it is imperative 
to fully evaluate patient’s immune status and find biomarkers that predict the effectiveness 
of immunotherapy. In addition, there is abundant evidence that exposure to radiation and 
chemotherapy drugs may affect the rate of DNA mutations in tumor cells, prompting the 
formation of some new antigens. As the current immunotherapy is always combined with 
radiotherapy and chemotherapy, determining the proper dose for each regimen is the prereq-
uisite for maximum benefit of combined therapy.
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Immunotherapy has a broad application prospect in the treatment of malignant tumors. The 
high frequency of esophageal cancer mutations and the effective results of immunotherapy 
highlighted in other gastrointestinal cancers provide strong evidence for the study of esopha-
geal cancer immunotherapy. Treatment strategies combined with existing or new treatment 
modes will be the direction of future esophageal cancer treatment.
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